Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

 

Feature | Atrial Fibrillation | January 30, 2019

January 30, 2019 — Updated atrial fibrillation (AFib) treatment guidelines released this week now recommend new oral...

The startup company Genetesis introduced a new cardiac imaging modalityit calls magnetocardiography. The scanner creates images from the biomagnetic activity of the heart, using the polarization and depolarization of the heart during the cardiac cycle. This was at AHA.18, AHA 2018 - the American Heart Association annual meeting

The startup company Genetesis introduced a new cardiac imaging modality it calls magnetocardiography. The scanner creates images from the biomagnetic activity of the heart, using the polarization and depolarization of the heart during the cardiac cycle.

Feature | AHA | January 14, 2019 | Dave Fornell, Editor

Here are a few of the takeaways from the clinical studies presented and new technology shown on the exhibit floor at...

Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019

January 10, 2019 — Aurobindo Pharma USA Inc. is conducting a voluntary recall of 80 lots of Amlodipine Valsartan...

The 2018 Most Popular Cardiology Topics - FDA approval of Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), and new pacemaker technologies.

The top two articles on DAIC from 2018 included the FDA approval of Andexxa, the first antidote indicated for patients treated with the anticoagulants rivaroxaban (Xarelto) and apixaban (Eliquis), and an article on new pacemaker technologies. 

Feature | January 04, 2019 | Dave Fornell, Editor

January 4, 2018 — Here is the top cardiology content on the Diagnostic and Interventional Cardiology (DAIC) website...

FDA Approves Portola Pharmaceuticals' Prior Approval Supplement for Andexxa Generation 2 Manufacturing Process
News | Antiplatelet and Anticoagulation Therapies | January 02, 2019

January 2, 2019 — The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals’ Prior Approval...

Daily Aspirin Use May Do More Harm Than Good for Healthy People
News | Antiplatelet and Anticoagulation Therapies | December 17, 2018

December 17, 2018 — Among otherwise healthy people, a daily dose of aspirin does not save lives and causes...

Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018

December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all...

Xarelto Reduces Blood Clot Events in High-Risk Cancer Patients
News | Cardio-oncology | December 07, 2018

December 7, 2018 — New data from the Phase 3 CASSINI...

A urine test can show patient compliance with taking their hypertension, high blood pressure, medications.
News | November 19, 2018

November 16, 2018 — A research team led by scientists and doctors in Leicester and the Netherlands has shown that a...

Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018

November 15, 2018 — AstraZeneca announced positive full results from the DECLARE-TIMI 58...

Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018

November 13, 2018 — A study in the current edition of the...

EMPRISE Study Shows Empagliflozin Reduces Heart Failure Hospitalization with new data presented at AHA 2018. #AHA18 #AHA2018
News | Heart Failure | November 07, 2018

November 6, 2018 – Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE)...

Overlay Init